ClinicalTrials.gg
CompletedNCT01288911Updated Dec 6, 2024Results posted

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

A Phase 2 interventional study of enzalutamide and bicalutamide in Prostatic Neoplasms, sponsored by Astellas Pharma Inc. Completed at 88 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
20th of 125
375 · median 52
Started
2011
with 3 others
Phase 2
65 of 125
8 open now
Registered
7th of 125
by date
Lead sponsor
7 of 125
Astellas Pharma Inc

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 20th largest by enrollment, is one of 4 that started in 2011, is one of 65 in phase 2, and was the 7th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study was to determine the efficacy and safety of oral enzalutamide compared to bicalutamide in castrate men with metastatic prostate cancer who have progressed while on Luteinizing Hormone Receptor Hormone (LHRH) agonist/antagonist or after receiving a bilateral orchiectomy.

Read the detailed description

An open-label period was added to the main protocol. Following unblinding at the end of the double-blind period and demonstration of a statistically significant advantage of enzalutamide over bicalutamide as assessed by the primary endpoint, all ongoing enzalutamide treated participants and ongoing or previous bicalutamide treated participants that met entry criteria were offered open-label enzalutamide at the discretion of the participant and study investigators.

03

Conditions studied

  • Prostatic Neoplasms

Keywords

  • Metastatic
  • MDV3100
  • Prostate
  • progressive
  • Cancer
  • enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Ongoing androgen deprivation therapy with a Luteinizing Hormone Receptor Hormone (LHRH) agonist or antagonist at a stable dose and schedule within 4 weeks of randomization or bilateral orchiectomy (i.e., surgical or medical castration)
  • disease documented by one of the following:

    • At least two bone lesions on bone scan, or
    • Soft tissue disease documented by computed tomography (CT)/ magnetic resonance imaging (MRI), or
    • Unequivocal pelvic adenopathy short axis > 2.0 cm in diameter by CT/MRI
  • Progressive disease at study entry defined as one or more of the following three criteria occurring in the setting of castrate levels of testosterone:

    • Prostate Specific Antigen (PSA) progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value should be ≥ 2 µg/L (2 ng/mL);
    • Soft tissue disease progression defined by (RECIST) 1.1;
    • Bone disease progression defined by two or more new lesions on bone scan
  • Asymptomatic or mildly symptomatic from prostate cancer (i.e. the score on the Brief Pain Inventory-Short Form (BPI-SF) Question #3 must be \< 4); no use of opiate analgesics for prostate cancer-related pain currently or anytime within 4 weeks prior to randomization
  • (ECOG) performance status of 0-1, including subjects with decreased performance status not attributed to progressive and symptomatic prostate cancer
  • Estimated of ≥ 12 months
  • Able to swallow the study drug and comply with study requirements
  • A male subject and his female spouse/partner who is of must use two acceptable methods of (one of which must include a condom as a barrier method of contraception) starting at Screening and continuing throughout the study period, and for 3 months after final study drug administration. Two acceptable forms of birth control include:

    1. Condom (barrier method of contraception), AND
    2. In addition to a condom, one of the following acceptable forms of contraception is required:

      • Established use of oral, injected or implanted hormonal methods of contraception.
      • Placement of an intrauterine device (IUD) or intrauterine system (IUS).
      • Barrier methods of contraception: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
      • Tubal ligation for at least 6 months prior to Screening
      • Vasectomy or other surgical castration at least 6 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • Prior cytotoxic chemotherapy for prostate cancer
  • Severe concurrent disease, infection, or comorbidity that would make the subject inappropriate for enrollment
  • Known or suspected brain and/or skull or active epidural disease
  • History of another within the previous 5 years other than curatively treated non-melanomatous skin cancer
  • Current or prior treatment with estrogens and/or drugs with anti-androgenic properties such as spironolactone > 50 mg/day, or progestational agents for the treatment of prostate cancer within 6 months prior to randomization
  • Current or prior use of ketoconazole for the treatment of prostate cancer
  • Use of antiandrogens within 6 weeks prior to randomization
  • Documented prior disease progression while receiving antiandrogens. Disease progression defined as PSA progression, radiographic progression and/or clinical deterioration.
  • Current or prior treatment with 5-α reductase inhibitors or anabolic steroids within 6 months prior to randomization
  • Prior use of systemic (the equivalent of 10 mg of prednisone) within 3 months prior to randomization or expectation of their use during the study
  • Radiation therapy to bone lesions or prostatic bed within 4 weeks prior to randomization
  • Major surgery within 2 months prior to randomization
  • History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization). Also, current or prior treatment with anti-epileptic medications for the treatment of seizures or history of loss of consciousness or within 12 months prior to randomization
  • cardiovascular disease including myocardial infarction within past six months or uncontrolled angina within past three months
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    Enzalutamide

    Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.

    Drug: enzalutamide

  • Active comparator
    Bicalutamide

    Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.

    Drug: bicalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment

    PFS is the time from randomization to the date of the first progression event detected. A progression event was defined as objective evidence of radiographic disease progression based on the assessments by the ICR, skeletal-related event, initiation of new antineoplastic therapy or death by any cause, whichever occurred first. Radiographic disease progression was defined as either a progression in soft tissue on computed tomography (CT)/magnetic resonance imaging (MRI) scan according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and/or a progression in bone lesions on bone scan (≥ 2 new bone lesions) confirmed by the next bone scan. A skeletal-related event was any radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression or change in antineoplastic therapy to treat bone pain. The initiation of new antineoplastic therapy included any new therapy for the treatment of disease progression after the study drug administration started.

    Time frame: From randomization until the data cut-off date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

Secondary outcomes

  1. PFS Based on Investigator Assessment

    PFS was calculated as the time from randomization to the date of the first progression event detected. A progression event was defined as objective evidence of radiographic disease progression based on the assessments by investigators, skeletal-related event, initiation of new antineoplastic therapy or death by any cause, whichever occurred first. Radiographic disease progression was defined as either a progression in soft tissue on CT/MRI scan according to RECIST 1.1, and/or a progression in bone lesions on bone scan (≥ 2 new bone lesions) confirmed by the next bone scan. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression or change in antineoplastic therapy to treat bone pain. The initiation of new antineoplastic therapy included any new therapy for the treatment of disease progression after the study drug administration started.

    Time frame: From randomization until the data cut-off date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  2. Prostate-specific Antigen (PSA) Response by Week 13

    The PSA response by Week 13 was defined as the percentage change from Baseline to the smallest PSA value after Baseline (i.e., a decrease of 100% represents the largest possible decrease to a value below the lower limit of quantification) and on or before day 99 (i.e., upper boundary of the Week 13 visit window). For participants with no decrease in PSA post-baseline by Week 13, the PSA response by Week 13 was the smallest increase in PSA up to day 99. For participants with no post-baseline PSA values up to day 99, the PSA response by Week 13 was set to missing. PSA was analyzed at a central laboratory.

    Time frame: Baseline to Week 13

  3. Best PSA Response

    The best PSA response was defined as the percentage change from Baseline to the smallest PSA value after Baseline including PSA results from samples taken after the study drug was stopped. For participants with no decrease in PSA post-baseline, the best PSA response was the smallest increase in PSA. For participants with no post-baseline PSA values, the PSA response was set to missing. PSA was analyzed at a central laboratory.

    Time frame: Baseline to the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  4. Time to PSA Progression

    Time to PSA progression was calculated as the time interval from the date of randomization to the date of first observation of PSA progression. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir (or above the baseline value for participants who did not have a decline in PSA post-baseline values), and confirmed by a second consecutive PSA assessment at least 3 weeks later. For participants with no documented PSA progression, the time to PSA progression was censored on the date the last PSA sample was taken.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  5. Time to PSA ≤ 4 ng/mL

    Time to PSA ≤ 4 ng/mL was defined as the time interval from the date of randomization to the first date a decline in PSA to a result of 4 ng/mL or below was recorded. In participants without PSA results ≤ 4 ng/mL, the time to PSA ≤ 4 ng/mL was censored on the date of the last PSA sample taken. Participants with a PSA result ≤ 4 ng/mL at Baseline, participants with no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  6. Time to ≥ 30% PSA Decline From Baseline

    The time to ≥ 30% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 30% was recorded. In participants without ≥ 30% PSA decline from Baseline, the time to ≥ 30% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  7. Time to ≥ 50% PSA Decline From Baseline

    The time to ≥ 50% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 50% was recorded. In participants without ≥ 50% PSA decline from Baseline, the time to ≥ 50% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  8. Time to ≥ 90% PSA Decline From Baseline

    The time to ≥ 90% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 90% was recorded. In participants without ≥ 90% PSA decline from Baseline, the time to ≥ 90% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  9. Radiographic PFS Based on ICR Assessment

    Radiographic PFS was calculated as the time interval from the date of randomization to the first date of radiographic disease progression. Radiographic disease progression was defined as either a progression in soft tissue on CT/MRI scan according to RECIST 1.1, and/or a progression in bone lesions (a minimum of 2 new bone lesions as compared to previous scan) on bone scan and confirmed by the next bone scan.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  10. Percentage of Participants With an Objective Response

    Response assessments were reported by ICR for target lesions in soft tissues and non-target lesions in soft tissues based on CT and/or MRI according to RECIST version 1.1. Objective response was defined as the number of participants achieving either a complete response (CR) or a partial response (PR) based on participant's best overall response assessed at the end of the treatment.

    Time frame: From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.

  11. Percentage of Participants With Adverse Events

    A serious adverse event was defined as any untoward medical occurrence that at any dose: ● Resulted in death ● Was life threatening ● Resulted in persistent or significant disability/incapacity ● Resulted in congenital anomaly or birth defect ● Required inpatient hospitalization or led to prolongation of hospitalization ● Other medically important events. Treatment-related indicates adverse events assessed by the Investigator as probably or possibly related to study treatment. Treatment emergent adverse events (TEAEs) were defined as adverse events (AEs) that started or worsened after starting administration of study drug through end of the study (i.e., the treatment-emergent period).

    Time frame: From initiation of study drug up to 30 days after last dose of study drug or the 30-day safety follow-up visit, whichever was last (Median duration of treatment was 11.6 months in enzalutamide arm and 5.8 in bicalutamide arm, 12.6 in the total arm).

07

Results

Posted Dec 3, 2015

Participant flow

Men with metastatic castration-resistant prostate cancer (mCRPC) were enrolled at 84 sites in a total of 8 countries.

Double-blind Period
Participant flow — Double-blind Period
MilestoneEnzalutamideBicalutamide
Started184191
Received treatment183189
Completed429
Not completed142182
Withdrew: Death117
Withdrew: Lost to follow-up02
Withdrew: Progressive disease75103
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject2526
Withdrew: Miscellaneous reason2942
Withdrew: Randomized but never received study drug12
Open-label Period (All Enzalutamide)
Participant flow — Open-label Period (All Enzalutamide)
MilestoneEnzalutamideBicalutamide
Started429
Received treatment429
Completed00
Not completed429
Withdrew: Death01
Withdrew: Lost to follow-up10
Withdrew: Progressive disease183
Withdrew: Withdrawal by subject10
Withdrew: Miscellaneous reason50
Withdrew: Transitioned to 9785-cl-0123 nct02960022175

Outcome measures

PrimaryProgression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment

PFS is the time from randomization to the date of the first progression event detected. A progression event was defined as objective evidence of radiographic disease progression based on the assessments by the ICR, skeletal-related event, initiation of new antineoplastic therapy or death by any cause, whichever occurred first. Radiographic disease progression was defined as either a progression in soft tissue on computed tomography (CT)/magnetic resonance imaging (MRI) scan according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and/or a progression in bone lesions on bone scan (≥ 2 new bone lesions) confirmed by the next bone scan. A skeletal-related event was any radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression or change in antineoplastic therapy to treat bone pain. The initiation of new antineoplastic therapy included any new therapy for the treatment of disease progression after the study drug administration started.

Time frame:
From randomization until the data cut-off date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment
monthsEnzalutamideBicalutamide
Progression Free Survival (PFS) Based on Independent Central Review (ICR) Assessment15.7 (11.5 to 19.4)5.8 (4.8 to 8.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.44 · 95% CI 0.34 to 0.57Estimated by use of Cox proportional hazards model.
SecondaryPFS Based on Investigator Assessment

PFS was calculated as the time from randomization to the date of the first progression event detected. A progression event was defined as objective evidence of radiographic disease progression based on the assessments by investigators, skeletal-related event, initiation of new antineoplastic therapy or death by any cause, whichever occurred first. Radiographic disease progression was defined as either a progression in soft tissue on CT/MRI scan according to RECIST 1.1, and/or a progression in bone lesions on bone scan (≥ 2 new bone lesions) confirmed by the next bone scan. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression or change in antineoplastic therapy to treat bone pain. The initiation of new antineoplastic therapy included any new therapy for the treatment of disease progression after the study drug administration started.

Time frame:
From randomization until the data cut-off date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
PFS Based on Investigator Assessment
monthsEnzalutamideBicalutamide
PFS Based on Investigator Assessment15.3 (11.8 to 19.4)5.7 (5.4 to 8.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.42 · 95% CI 0.33 to 0.55Estimated by use of Cox proportional hazards model.
SecondaryProstate-specific Antigen (PSA) Response by Week 13

The PSA response by Week 13 was defined as the percentage change from Baseline to the smallest PSA value after Baseline (i.e., a decrease of 100% represents the largest possible decrease to a value below the lower limit of quantification) and on or before day 99 (i.e., upper boundary of the Week 13 visit window). For participants with no decrease in PSA post-baseline by Week 13, the PSA response by Week 13 was the smallest increase in PSA up to day 99. For participants with no post-baseline PSA values up to day 99, the PSA response by Week 13 was set to missing. PSA was analyzed at a central laboratory.

Time frame:
Baseline to Week 13
Reported as:
Median · percent change
Prostate-specific Antigen (PSA) Response by Week 13
percent changeEnzalutamideBicalutamide
Prostate-specific Antigen (PSA) Response by Week 13-89.03 (-100.0 to 287.7)0.36 (-98.5 to 25700.0)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Wilcoxon rank sum test · p = <0.0001
SecondaryBest PSA Response

The best PSA response was defined as the percentage change from Baseline to the smallest PSA value after Baseline including PSA results from samples taken after the study drug was stopped. For participants with no decrease in PSA post-baseline, the best PSA response was the smallest increase in PSA. For participants with no post-baseline PSA values, the PSA response was set to missing. PSA was analyzed at a central laboratory.

Time frame:
Baseline to the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · percent change
Best PSA Response
percent changeEnzalutamideBicalutamide
Best PSA Response-92.96 (-100.0 to 287.7)0.18 (-99.8 to 25700.0)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Wilcoxon rank sum test · p = <0.0001
SecondaryTime to PSA Progression

Time to PSA progression was calculated as the time interval from the date of randomization to the date of first observation of PSA progression. PSA progression was defined as a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir (or above the baseline value for participants who did not have a decline in PSA post-baseline values), and confirmed by a second consecutive PSA assessment at least 3 weeks later. For participants with no documented PSA progression, the time to PSA progression was censored on the date the last PSA sample was taken.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Time to PSA Progression
monthsEnzalutamideBicalutamide
Time to PSA Progression19.4 (16.6 to NA)5.8 (5.6 to 8.3)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.28 · 95% CI 0.20 to 0.39Estimated by use of Cox proportional hazards model.
SecondaryTime to PSA ≤ 4 ng/mL

Time to PSA ≤ 4 ng/mL was defined as the time interval from the date of randomization to the first date a decline in PSA to a result of 4 ng/mL or below was recorded. In participants without PSA results ≤ 4 ng/mL, the time to PSA ≤ 4 ng/mL was censored on the date of the last PSA sample taken. Participants with a PSA result ≤ 4 ng/mL at Baseline, participants with no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Time to PSA ≤ 4 ng/mL
monthsEnzalutamideBicalutamide
Time to PSA ≤ 4 ng/mL3.0 (2.9 to 5.6)NA (NA to NA)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 5.07 · 95% CI 3.18 to 8.09Estimated by use of Cox proportional hazards model.
SecondaryTime to ≥ 30% PSA Decline From Baseline

The time to ≥ 30% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 30% was recorded. In participants without ≥ 30% PSA decline from Baseline, the time to ≥ 30% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Time to ≥ 30% PSA Decline From Baseline
monthsEnzalutamideBicalutamide
Time to ≥ 30% PSA Decline From Baseline2.8 (2.8 to 2.8)NA (NA to NA)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 5.55 · 95% CI 3.96 to 7.79Estimated by use of Cox proportional hazards model.
SecondaryTime to ≥ 50% PSA Decline From Baseline

The time to ≥ 50% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 50% was recorded. In participants without ≥ 50% PSA decline from Baseline, the time to ≥ 50% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Time to ≥ 50% PSA Decline From Baseline
monthsEnzalutamideBicalutamide
Time to ≥ 50% PSA Decline From Baseline2.8 (2.8 to 2.8)NA (NA to NA)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 7.01 · 95% CI 4.83 to 10.16Estimated by use of Cox proportional hazards model.
SecondaryTime to ≥ 90% PSA Decline From Baseline

The time to ≥ 90% PSA decline from Baseline was defined as the time interval from the date of randomization to the first date a PSA decline from Baseline of at least 90% was recorded. In participants without ≥ 90% PSA decline from Baseline, the time to ≥ 90% PSA decline from Baseline was censored on the date of the last PSA sample taken. Participants who had no Baseline PSA and participants with no post-baseline PSA results were censored on the date of randomization.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Time to ≥ 90% PSA Decline From Baseline
monthsEnzalutamideBicalutamide
Time to ≥ 90% PSA Decline From Baseline5.4 (3.0 to 5.7)NA (NA to NA)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = <0.0001 · Hazard ratio (hr): 13.91 · 95% CI 7.23 to 26.79Estimated by use of Cox proportional hazards model.
SecondaryRadiographic PFS Based on ICR Assessment

Radiographic PFS was calculated as the time interval from the date of randomization to the first date of radiographic disease progression. Radiographic disease progression was defined as either a progression in soft tissue on CT/MRI scan according to RECIST 1.1, and/or a progression in bone lesions (a minimum of 2 new bone lesions as compared to previous scan) on bone scan and confirmed by the next bone scan.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Median · months
Radiographic PFS Based on ICR Assessment
monthsEnzalutamideBicalutamide
Radiographic PFS Based on ICR AssessmentNA (25.6 to NA)16.4 (11.1 to 18.1)
Statistical analysis
  • Enzalutamide vs Bicalutamide · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.51 · 95% CI 0.36 to 0.74Estimated by use of Cox proportional hazards model.
SecondaryPercentage of Participants With an Objective Response

Response assessments were reported by ICR for target lesions in soft tissues and non-target lesions in soft tissues based on CT and/or MRI according to RECIST version 1.1. Objective response was defined as the number of participants achieving either a complete response (CR) or a partial response (PR) based on participant's best overall response assessed at the end of the treatment.

Time frame:
From randomization until the data cutoff date of 19 October 2014, median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsEnzalutamideBicalutamide
Percentage of Participants With an Objective Response15.82.6
SecondaryPercentage of Participants With Adverse Events

A serious adverse event was defined as any untoward medical occurrence that at any dose: ● Resulted in death ● Was life threatening ● Resulted in persistent or significant disability/incapacity ● Resulted in congenital anomaly or birth defect ● Required inpatient hospitalization or led to prolongation of hospitalization ● Other medically important events. Treatment-related indicates adverse events assessed by the Investigator as probably or possibly related to study treatment. Treatment emergent adverse events (TEAEs) were defined as adverse events (AEs) that started or worsened after starting administration of study drug through end of the study (i.e., the treatment-emergent period).

Time frame:
From initiation of study drug up to 30 days after last dose of study drug or the 30-day safety follow-up visit, whichever was last (Median duration of treatment was 11.6 months in enzalutamide arm and 5.8 in bicalutamide arm, 12.6 in the total arm).
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsEnzalutamideBicalutamideTotal Enzalutamide
TEAEs94.594.294.8
Related TEAEs66.749.767.2
Deaths5.51.65.7
Serious TEAEs33.323.836.5
Drug regimen-related serious TEAEs6.63.26.8
TEAEs leading to discontinuation29.523.831.3
Drug regimen-related TEAEs leading to discon.7.75.37.8
TEAEs leading to study drug interruption10.47.910.4

Adverse events

Collected over From initiation of study drug up to 30 days after the last dose of study drug or the 30-day safety follow-up visit, whichever occurred last. Median duration of treatment was 11.6 months in the enzalutamide arm and 5.8 months in the bicalutamide arm in the double-blind period. In the open-label period, the median duration of treatment was 21.6 months in participants who previously received enzalutamide and 20.9 months in participants who previously received bicalutamide.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Period: Enzalutamide11/141 (7.8%)49/141 (34.8%)123/141 (87.2%)
Double-blind Period: Bicalutamide7/180 (3.9%)43/180 (23.9%)149/180 (82.8%)
Open-label Period: Enzalutamide/Enzalutamide0/42 (0%)18/42 (42.9%)42/42 (100%)
Open-label Period: Bicalutamide/Enzalutamide1/9 (11.1%)4/9 (44.4%)9/9 (100%)
Most frequent serious events
Showing 10 of 153
Most frequent serious events
EventDouble-blind Period: EnzalutamideDouble-blind Period: BicalutamideOpen-label Period: Enzalutamide/EnzalutamideOpen-label Period: Bicalutamide/Enzalutamide
Atrioventricular blockCardiac disorders0/1410/1800/421/9
BradycardiaCardiac disorders0/1410/1801/421/9
Cardiogenic shockCardiac disorders0/1410/1800/421/9
Ventricular fibrillationCardiac disorders0/1410/1800/421/9
BacteraemiaInfections and infestations1/1410/1800/421/9
InfectionInfections and infestations0/1410/1800/421/9
FallInjury, poisoning and procedural complications1/1410/1800/421/9
ArthralgiaMusculoskeletal and connective tissue disorders0/1411/1800/421/9
IncoherentNervous system disorders0/1410/1800/421/9
Transient ischaemic attackNervous system disorders1/1410/1801/421/9
Most frequent other events
Showing 10 of 82
Most frequent other events
EventDouble-blind Period: EnzalutamideDouble-blind Period: BicalutamideOpen-label Period: Enzalutamide/EnzalutamideOpen-label Period: Bicalutamide/Enzalutamide
ArthralgiaMusculoskeletal and connective tissue disorders16/14127/1809/425/9
Hot flushVascular disorders15/14117/18012/424/9
FatigueGeneral disorders35/14138/18018/423/9
HeadacheNervous system disorders11/1416/1808/423/9
HypertensionVascular disorders18/14114/18013/420/9
Back painMusculoskeletal and connective tissue disorders29/14134/18011/421/9
NauseaGastrointestinal disorders18/14133/18010/420/9
DiarrhoeaGastrointestinal disorders16/14115/1805/422/9
DyspepsiaGastrointestinal disorders5/1414/1801/422/9
FallInjury, poisoning and procedural complications9/1416/1804/422/9

Baseline characteristics

The baseline analysis population consisted of all participants that were randomized to receive study drug.

Age, Continuous
Age, Continuous(years)EnzalutamideBicalutamideTotal
Mean70.3 ± 9.2271.1 ± 8.8970.7 ± 9.05
Age, Customized
Age, Customized(participants)EnzalutamideBicalutamideTotal
< 65 years454792
65-75 years8580165
> 75 years5464118
Sex: Female, Male
Sex: Female, Male(Participants)EnzalutamideBicalutamideTotal
Female000
Male184191375
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EnzalutamideBicalutamideTotal
White172176348
Black or African American81018
Asian325
Native Hawaiian or Other Pacific Islander112
Other022
Ethnicity
Ethnicity(Participants)EnzalutamideBicalutamideTotal
Not Hispanic or Latino184187371
Hispanic or Latino044
LHRH agonist/antagonist initiation or bilateral orchiectomy relative to diagnosis of metastasis
LHRH agonist/antagonist initiation or bilateral orchiectomy relative to diagnosis of metastasis(Participants)EnzalutamideBicalutamideTotal
Before diagnosis of metastasis8776163
After diagnosis of metastasis97115212
08

Study locations

88 sites
  • Site US1934
    Homewood, Alabama 35209, United States
  • Site US1527
    Anchorage, Alaska 99503, United States
  • Site US3026
    Tucson, Arizona 85715, United States
  • Site US2977
    Highland, California 92346, United States
  • Site US3630
    San Diego, California 92123, United States
  • Site US2935
    Denver, Colorado 80211, United States
  • Site US2945
    Middlebury, Connecticut 06762, United States
  • Site US2014
    Melrose Park, Illinois 60160, United States
  • Site US2067
    Springfield, Illinois 62703, United States
  • Site US2027
    Jeffersonville, Indiana 47130, United States
  • Site US1838
    West Des Moines, Iowa 50266, United States
  • Site US62
    Kansas City, Kansas 66160-7233, United States
  • Site US2976
    Baltimore, Maryland 21201, United States
  • Site US3182
    Bethesda, Maryland 20889-5600, United States
  • Site US2975
    Ann Arbor, Michigan 48109, United States
  • Site US892
    Grand Rapids, Michigan 49546, United States
  • Site US20
    Minneapolis, Minnesota 55455, United States
  • Site US3078
    Billings, Montana 59101, United States
  • Site US2968
    Lawrenceville, New Jersey 08648, United States
  • Site US3025
    Poughkeepsie, New York 12601, United States
  • Site US1675
    Rochester, New York 14642, United States
  • Site US2934
    Staten Island, New York 10304, United States
  • Site US81
    Chapel Hill, North Carolina 27599, United States
  • Site US2104
    Greensboro, North Carolina 27403, United States
  • Site US44
    Cincinnati, Ohio 45267, United States
  • Site US2185
    Columbus, Ohio 43221, United States
  • Site US1598
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Site US1680
    Lancaster, Pennsylvania 17604, United States
  • Site US2926
    Myrtle Beach, South Carolina 29572, United States
  • Site US1657
    Nashville, Tennessee 37209, United States
  • Site US464
    Houston, Texas 77030, United States
  • Site US2978
    San Antonio, Texas 78229, United States
  • Site US1653
    Virginia Beach, Virginia 23462, United States
  • Site US1580
    Burien, Washington 98166, United States
  • Site US1709
    Wenatchee, Washington 98801, United States
  • Site US51
    Milwaukee, Wisconsin 53226, United States
  • Site BE3015
    Brussels, 1090, Belgium
  • Site BE1322
    Gent, 9000, Belgium
  • Site BE3018
    Kortrijk, 8500, Belgium
  • Site BE3288
    Leuven, 3000, Belgium
  • Site BE3289
    Liege, Belgium
  • Site BE3013
    Turnhout, 2300, Belgium
  • Site CA3104
    Calgary, Alberta T2V 1P9, Canada
  • Site CA3242
    Abbotsford, British Columbia V2S 3N5, Canada
  • Site CA2646
    Kingston, Ontario K7L 2V7, Canada
  • Site CA166
    Toronto, Ontario M4N 3M5, Canada
  • Site CA3084
    Toronto, Ontario M5G 2M9, Canada
  • Site CA2984
    Granby, Quebec J2G 8Z9, Canada
  • Site CA170
    Montreal, Quebec H3G 1A4, Canada
  • Site DK3354
    Aalborg, 9000, Denmark
  • Site DK3356
    Aarhus, 8200, Denmark
  • Site DK1857
    Copenhagen, 2200, Denmark
  • Site DK1263
    Herlev, 2730, Denmark
  • Site FR1091
    Creteil, 94010, France
  • Site FR3009
    Lille, 59037, France
  • Site FR442
    Lyon Cedex 3, 69437, France
  • Site FR3002
    Paris Cedex 10, 75020, France
  • Site FR3003
    Poitiers Cedex, 86000, France
  • Site FR3000
    Rennes Cedex, 35033, France
  • Site FR3007
    Rouen, 76031, France
  • Site FR3005
    Suresnes Cedex, 92151, France
  • Site DE4000
    Nuertingen, Baden-Wuerttemberg 72622, Germany
  • Site DE2989
    Aachen, 51074, Germany
  • Site DE3287
    Bergisch Gladbach, D-51465, Germany
  • Site DE2993
    Bonn, 53105, Germany
  • Site DE2995
    Bonn, 53111, Germany
  • Site DE2994
    Bonn, 53117, Germany
  • Site DE2990
    Hamburg, 22081, Germany
  • Site DE3270
    Hannover, 30625, Germany
  • Site DE2992
    Reutlingen, 72764, Germany
  • Site DE3286
    Waldshut-Tiengen, 29761, Germany
  • Site DE2988
    Wuppertal, 42103, Germany
  • Site RO3042
    Bucharest, RO 022328, Romania
  • Site RO3039
    Bucharest, RO 050659, Romania
  • Site RO3035
    Bucharest, 041345, Romania
  • Site GB3029
    Bristol, UK BS2 8HW, United Kingdom
  • Site GB3027
    London, UK SE19RT, United Kingdom
  • Site GB3030
    London, UK SW17 0QT, United Kingdom
  • Site GB3028
    Cardiff, Wales CF14 4XW, United Kingdom
  • Site GB3244
    Belfast, BT9 7AB, United Kingdom
  • Site GB2702
    Cambridge, CB2 0QQ, United Kingdom
  • Site GB3166
    Glasgow, G12 0YN, United Kingdom
  • Site GB1862
    Leicher, LE5 4PW, United Kingdom
  • Site GB3163
    London, NW1 2PG, United Kingdom
  • Site GB2624
    Manchester, M20 4BX, United Kingdom
  • Site GB3355
    Merseyside, CH63 4JY, United Kingdom
  • Site GB3245
    Northwood, Middlesex, HA6 2RN, United Kingdom
  • Site GB3290
    Preston, PR2 9HT, United Kingdom
09

References and documents

Publications

  • Heidenreich A, Chowdhury S, Klotz L, Siemens DR, Villers A, Ivanescu C, Holmstrom S, Baron B, Wang F, Lin P, Shore ND. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Eur Urol. 2017 Apr;71(4):534-542. doi: 10.1016/j.eururo.2016.07.027. Epub 2016 Aug 3. PubMed 27497762 ↗
  • Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14. PubMed 26774508 ↗

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2011 to primary completion in Oct 2014, 42 months.

Results were first posted in Dec 2015, 1 year 1 month after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 42 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2011
First posted
Feb 3, 2011
StartActual
Mar 22, 2011
Primary completionActual
Oct 19, 2014
CompletionActual
Nov 8, 2017
Results first posted
Dec 3, 2015
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01288911
Collaborators
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Feb 3, 2011
Start date
Mar 22, 2011
Primary completion
Oct 19, 2014
Completion
Nov 8, 2017
Results posted
Dec 3, 2015
Last update
Dec 6, 2024

Study contacts

Principal Investigator
principal investigator · Carolina Urologic Research Center
Associate Medical Science Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion